Clinical Trial

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

Study acronym: IPROC
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.
Protocol Amendment History 1 change
notable Primary completion pushed: 2026-06-30 -> 2026-12-31 2026-07-15
Trial Details
NCT Number NCT04918186
Lead Sponsor Canadian Cancer Trials Group
Collaborators: Cancer Research Institute, New York City, AstraZeneca, BioAtla, Inc.
Conditions Ovarian Cancer
Enrollment 60 participants
Start Date 2022-05-03
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-21